OOIR: Observatory of International Research

Papers

(The median citation count of JACC-Heart Failure is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Reply	262
Reply	203
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction	169
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status	133
Editorial Board	111
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia	92
Correction	87
Eating to Prevent Both Heart and Planetary Failure	84
Curing Ourselves of Toxic Positivity for Hospital-at-Home	75
Full issue PDF	72
Wearable Remote Patient Monitoring Devices	70
Revisiting ICD Therapy for Primary Prevention	69
Associations Between Urinary Metal Levels and Incident Heart Failure	68
Pulmonary Artery Catheter Timing and Outcomes for Patients With Cardiogenic Shock	66
Clinical Implications of the P.V142I TTR Variant	66
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies	65
Reply	64
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction	64
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure	61
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	61
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans	60
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States	55
Long-Term Effects of Sotatercept on Right Ventricular Function	54
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure	54
Reply	52

Exercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction	52
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome	51
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function	51
Opportunities for Change in Home Health Care in Heart Failure	50
Developing a System for Best Performance for Cardiac Transplantation	49
Predictors of Incident Heart Failure Diagnosis Setting	49
Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death	47
Challenges Addressing Prognosis in Advanced Heart Failure	46
The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis	46
Body Composition and Survival in Patients With Heart Failure	46
Clinical Utility of the H2FPEF Score in Patients With Early Atrial Fibrillation	45
The Path Toward a More Equitable Transplant System	44
GDF-15 in Cardiovascular Disease	43
Cardiopulmonary Exercise Testing With Exercise Echocardiography to Assess Treatment Response in Transthyretin Amyloid Cardiomyopathy	42
Prognosis for Acute Myocarditis	41
Full Issue PDF	40
Obesity and Heart Failure in Patients With a Reduced Ejection Fraction	40
Compensation Models in Heart Failure	39
Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical Sensors	39
Peripheral Venous Pressure Measured With a Novel Miniature Transducer in Heart Failure Patients	39
NT-proBNP	38
Are We Waiting Too Long to Implant Cardiac Resynchronization Therapy Devices in Patients With Heart Failure and Reduced Left Ventricular Function?	37
From Dispensing Pills to Building Pillars	37
Closing the Gap, A Commentary on Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute Heart Failure	36
High NT-proBNP in Heart Failure	36
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design	36
Eplerenone for Nonobstructive Hypertrophic Cardiomyopathy	36
Reply	35
Hyperkalemia-Related Heart Failure Therapy Discontinuation and the Association With Outcomes in Patients With Heart Failure	35
Effects of Acute Phase Intensive Exercise Training in Patients With Acute Decompensated Heart Failure	33
Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups	33
Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure	33
Impact of SGLT2 Inhibitors on Serum Sodium in Heart Failure With Reduced Ejection Fraction	32
Endothelin Receptor Antagonists and Risk of Heart Failure in CKD	32
Reply	32
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction	32
Thank You for the Privilege	31
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status	31
Heart Failure With Preserved Ejection Fraction	30
Racial and Genetic Differences	30
Inhibiting Both Neprilysin and Phosphodiesterase Type 9	30
Advanced Heart Failure in the Cardiac Intensive Care Unit	30
Heart Failure in Women	29
Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment	29
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events	29
Absence of Atrial Fibrillation Reduction in REDUCE LAP-HF II	29
A Woman's Work Is Never Done	29
Hospital at Home as a Novel Care Strategy for Worsening Heart Failure	28
Every Journey Needs a Guide	28
Influence of Impaired Conduction on Exercise Hemodynamics in Patients With Preserved Ejection Fraction	28

Value of Invasive Hemodynamic Assessments in Patients Supported by Continuous-Flow Left Ventricular Assist Devices	28
STRONG-HF	28
Reevaluating Growth Hormone Therapy in HFrEF	27
Facts and Fallacies of Body Composition Analysis in Heart Failure	26
Guideline Recommendations for Sudden Cardiac Death Prevention in Patients With Hypertrophic Cardiomyopathy	26
Reply	26
Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry	25
Diabetes Therapy With SGLT2i After Heart Transplant	25
Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device	25
SGLT2 Inhibitors and Serious Renal Events Among Patients With Heart Failure With Reduced Ejection Fraction	25
Therapeutic Options in Ambulatory Advanced Heart Failure	25
Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin	25
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction	24
Risk Factors and Temporal Trends of Maternal Heart Failure	24
Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure	24
SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity	24
Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten	23
Smoking Cessation Reduces the Risk of Heart Failure	22
Obesity and Weight Loss Strategies for Patients With Heart Failure	22
Upper Body Hypoxemia During ECMELLA	22
Chloride in Heart Failure	22
Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure	22
Management of Heart Failure–Related Cardiogenic Shock	22
Understanding and Investigating Sex-Based Differences in Heart Transplantation	22
Pregnancy-Induced Hypertensive Disorder and Risks of Future Ischemic and Nonischemic Heart Failure	21
Natriuretic Peptides and Stratification for ICD Therapy in Nonischemic Heart Failure	21
Editorial Board	21
Winning the Battle of Timely Guideline-Directed Medical Therapy Titration	21
Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction	21
Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post–Coronavirus Disease	21
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure	21
Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure	21
Moving From Prompts to Praxis With Remote Monitoring	20
Illuminating a Hidden Risk	20
From Better Models to Better Care	20
Full issue PDF	20
Treatment of Obesity in Heart Failure	20
The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy	20
Tafamidis in Octogenarians	20
Expanded Definition of Worsening Heart Failure	19
Contemporary Epidemiology, Management, and In-Hospital Outcomes of Acute Myocarditis	19
Beyond Coronary Atherosclerosis	19
Identifying Predictors for Heart Failure Outcomes in Phospholamban p.(Arg14del)–Positive Individuals	19
Toward a Streamlined Optimization Protocol for Patients With Heart Failure With Reduced Ejection Fraction	19
Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes	19
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis	19
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure	19
Redefining Pre–Heart Failure With Cardiac Biomarkers	18
Any Cardiac Influence of the Structural and Functional Brain Changes in Patients With Takotsubo Syndrome?	18
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population	18
Full issue PDF	18
Isolating Noise From Signals in the Air	18
Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction	18
To Infinity and Beyond	18
Setting the Diagnosis of Heart Failure	18
Critical Importance of Genetic Screening in Family Members	17
Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes	17
Walking the Line Between Failure and Remission	17
Perirenal Adipose Tissue Is Associated With Renal Dysfunction and Abnormal Hemodynamics in Patients With HFpEF	17
Effective and Cost-Conscious Utilization of SGLT2 Inhibitors	17
Instructions for Authors	17
Bounded Rationality and Clinical Guidance Documents for Heart Failure	17
Jump Starting the Heart	17
Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients	17
Health Status Predicts Short- and Long-Term Risk of Composite Clinical Outcomes in Acute Heart Failure	17
To ‘Plant or Not to ‘Plant, That Is the Question	17
The Jury Is Still Out on A-Type Natriuretic Peptide Deficiency Relative to B-Type Natriuretic Peptides	17
Cardiac Magnetic Resonance in the Evaluation and Management of Nonischemic Cardiomyopathies	16
Pressure From Within and Without in Heart Failure With Preserved Ejection Fraction	16
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial	16
Gender and Race Differences in HeartMate3 Left Ventricular Assist Device as a Bridge to Transplantation	16
Physical Activity Trajectories Preceding Incident Heart Failure	16
Full Issue PDF	16
Initial Experience With Aeson Total Artificial Heart in Cardiogenic Shock Patients on Extracorporeal Life Support	16
Articulating the JACC Journals’ Direction in Times of Global Change	16
Patterns of Left Ventricular Regional Wall Motion Abnormalities After Brain Death and Their Clinical Significance	16
Automated Identification of Heart Failure With Reduced Ejection Fraction Using Deep Learning-Based Natural Language Processing	16
The Link Between Heart Failure and Neurodegeneration	16
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction	15
HFpEF Scores	15

Reply	15
Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides	15
Depressive Symptoms and Incident Heart Failure Risk in the Southern Community Cohort Study	15
Impact of Female Sex on Cardiogenic Shock Outcomes	15
Global Heart Failure Trends in Young Adults	15
All That Glitters Is Not Gold	15
Istaroxime in HFpEF	15
Bereavement and Mortality in Heart Failure	15
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of HFrEF	15
Navigating Advanced Heart Failure in the Shadow of Primary Graft Dysfunction	15
Disease Penetrance in Genotype-Positive But Clinically Unaffected Relatives From Families With Dilated Cardiomyopathy	15
Streamlined Heart Failure Optimization Protocol for Patients With Reduced Left Ventricular Ejection Fraction	15
Pulmonary Artery Denervation for Combined Pre– and Post–Capillary Pulmonary Hypertension	15
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States	15
Refining Endpoint Measures in Clinical Trials for Hypertrophic Cardiomyopathy	15
Shedding Light on the Darkness of MYH7 Cardiomyopathies	14
Contemporary American and European Guidelines for Heart Failure Management	14
Gamified Behavioral Science Intervention to Enhance Trial Enrollment	14
Deactivation of Left Ventricular Assist Devices at the End of Life	14
Heart Failure With Preserved Ejection Fraction in Patients With Atrial Fibrillation	14
Correction	14
Targeting Inflammation in Heart Failure Prevention	14
Impact of Coronary Artery Disease in Women With Newly Diagnosed Heart Failure and Reduced Ejection Fraction	13
Low Serum Ferritin Might Predict Incident Heart Failure	13
The Lure of Cardiac Metabolism in the Diagnosis, Prevention, and Treatment of Heart Failure	13
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy	13
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction	13
Reply	13
Correction	13
Prevalence and Incidence of Pre-HF Among Hispanics/Latinos	13
Pre–Heart Failure Longitudinal Change in a Hispanic/Latino Population-Based Study	13
Exertional Dyspnea Can Now Be Graded Using Normative Reference Equations	13
Reply	13
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction	12
Navigating the Global Burden of Pulmonary Arterial Hypertension	12
Medication Optimization Clinic	12
Thin Evidence, Heavy Need	12
Nonsteroidal and Steroidal Mineralocorticoid Antagonists	12
Early Reduction of Pulmonary Artery Pressures Is Associated With Improved Mortality Among Medicare Beneficiaries With Heart Failure	12
The Enigma of Natriuretic Peptides	12
Multifactorial Predisposition in Biopsy-Proven Autoimmune and Viral Myocarditis	12
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy	12
Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure	12
Patient Preference Should Take Precedence in Status 2 Listing for Heart Transplantation	12
Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction	12
Reducing Pediatric Heart Failure Readmissions	12
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial	12
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF	12
m-Health Based Cardiac Rehabilitation Program for Management of Older Patients With HFpEF	11
Full issue PDF	11
Cardiac Magnetic Resonance Imaging vs Coronary Angiography as Primary Strategy in Newly Diagnosed Heart Failure	11
The HeartMate 3 Risk Score	11
Pregnancy as a Sentinel Event	11
Reflections on Early Rehabilitation in Acute Heart Failure	11
Standardizing Histopathological Evaluation of Resected Myocardium in Obstructive Hypertrophic Cardiomyopathy	11
Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients	11
Cost and Value in Contemporary Heart Failure Clinical Guidance Documents	11
Fibrosis Biomarkers Predict Cardiac Reverse Remodeling	11
Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation	11
Aging in Heart Failure	11
Better 3 Hours Too Soon Than 1 Minute Late	11
Coronary Artery Disease Is Still a Major Cause of Heart Failure	11
Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure	11
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	11
Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF	11
Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy	10
Renal Compression in Heart Failure	10
When the Data Changes, So Should We	10
“Pharmacoequity” in Heart Failure Treatment	10
Low Education Levels Linked to Increased Mortality Following Acute Heart Failure Hospitalization in Brazil	10
Management of Patients With Impella 5.5 Left Ventricular Assist Devices on a Cardiovascular Stepdown Unit	10
Reply	10
Correction	10
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction	10
Trajectories of Kidney Function in Heart Failure Over a 15-Year Follow-Up	10
Promoting Representation in Heart Failure Clinical Trials	10
24-Month Outcomes of Endovascular Baroreflex Amplification With the MobiusHD Device in Heart Failure With Reduced Ejection Fraction	10
REPLY	10
Redefining Boundaries in Heart Failure Care	10
Information for Authors	10
Guideline-Recommended Therapy Following Hospitalization for Heart Failure	10
Heart Failure and the Risk of Stroke	10
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction	10
Officers Page	10
Iron Deficiency Definition and Management in Patients With Heart Failure	10
Hypertrophic Cardiomyopathy With Midventricular Obstruction Is Not Nonobstructive Hypertrophic Cardiomyopathy	10
Measures to Improve Trial Enrollment	9
Moving the Goalposts to Improve Postdischarge Outcome for Patients With Cardiogenic Shock and Acute MI	9
Ending the Fear Depriving Patients With HFpEF and CKD of Lifesaving Therapies	9
Association of Extracoronary Calcification and Incident Heart Failure in the Multiethnic Study of Atherosclerosis (MESA)	9
Migration Matters	9
Further Refining the In-Hospital Risk Assessment of Patients Presenting With Uncomplicated Acute Myocarditis	9
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF	9
Toward Equitable Heart Transplant Outcomes	9
Sex, Temporary Mechanical Circulatory Support, and Heart Transplantation	9